Effect of Pirarubicin Infusion after TURBT on VEGF, FGF, MMP-s and Prognosis in Patients with Superficial Bladder Cancer

  • Jianhua Long
Keywords: TURBT; pirarubicin;Superficial bladder cancer; VEGF; FGF; MMP-s and prognosis

Abstract

This paper investigate the effect of pirarubicin infusion on vascular endothelial growth factor (VEGF), fibroblast growth factor (fibroblast growth factor), matrix metalloproteinase-s (MMP-s) and prognosis in patients with superficial bladder cancer after transurethral resection of bladder tumors (TURBT). The control group was treated with TURBT alone, and the treatment group was treated with pirarubicin after TURBT. The changes of VEGF, FGF and MMP-s levels and prognosis were compared between the two groups after treatment. The levels of vascular endothelial growth factor, alpha fibroblast growth factor, beta fibroblast growth factor, MMP-2 and MMP-9 in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the recurrence rates of 1, 2 and 3 years in the treatment group were significantly lower than those in the control group (P < 0.05). There was no significant difference in 1-year survival rate between the two groups after treatment (P > 0.05). The 2-year and 3-year survival rates in the treatment group were significantly higher than those in the control group (P < 0.05). Complications such as bladder irritation sign, bladder perforation and thrombocytopenia in the treatment group were significantly lower than those in the control group (P < 0.05). Intravenous pirarubicin for superficial bladder cancer after TURBT can improve the serum factor level, reduce the recurrence rate and improve the survival rate of patients. The incidence of adverse reactions is low and the clinical application value is wide.

Published
2019-09-01